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Purpose: The non–vitamin K antagonist oral anti-
coagulants (NOACs), dabigatran, rivaroxaban, and
apixaban, provide several advantages over vitamin K
antagonists, such as warfarin. Little is known about
the trends of prescribing OACs in Canada. In this
study we analyzed changes in prescription volumes for
OAC drugs since the introduction of the NOACs in
Canada overall, by province and by physician
specialty.
Methods: Canadian prescription volumes for war-
farin, dabigatran, rivaroxaban, and apixaban from
January 2008 to June 2014 were obtained from the
Canadian Compuscript Audit of IMS Health Canada
Inc and were analyzed by physician specialty at the
national and provincial levels. Total prescriptions by
indication were calculated based on data from the
Canadian Disease and Therapeutic Index for all OAC
indications and for each commonly prescribed dose of
dabigatran (75, 110, and 150 mg), rivaroxaban (10,
15, and 20 mg), and apixaban (2.5 and 5 mg).
Findings: The overall number of OAC prescriptions
in Canada has increased annually since 2008. With
the availability of the NOACs, the proportion of total
OAC prescriptions attributable to warfarin has stead-
ily decreased, from 99% in 2010 to 67% by June
2014, and the absolute number of warfarin prescrip-
tions has been decreasing since February 2011. The
greatest decline in proportionate warfarin prescrip-
tions was in Ontario. In general, the increase of
NOAC prescriptions coincided with the introduction
of provinces’ reimbursement of NOAC prescription
costs. The proportion of total OAC prescriptions2506represented by the NOACs varied by specialty, with
the greatest proportionate prescribing found among
orthopedic surgeons, cardiologists, and neurologists.
Implications: Since their approval, the NOACs have
represented a growing share of total OAC prescriptions
in Canada. This trend is expected to continue because
the NOACs are given preference over warfarin in
guidelines on stroke prevention in patients with atrial
ﬁbrillation, because of growing physician experience,
and due to the emergence of potential new indications.
An understanding of the current prescribing patterns
will help to encourage knowledge translation and
possibly inﬂuence policy/reimbursement strategies. (Clin
Ther. 2015;37:2506–2514) & 2015 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
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trends.INTRODUCTION
For decades, vitamin K antagonists, such as warfarin,
were the only oral anticoagulant (OAC) agents in-
dicated for the long-term prevention and treatment of
arterial and venous thrombosis. Although warfarin is
effective, its use is complicated by its numerous
drug and food interactions, as well as the need for
individualized patient dosing, requiring regularVolume 37 Number 11
J.I. Weitz et al.monitoring of coagulation to optimize efﬁcacy and
tolerability.1,2 The non–vitamin K antagonist OACs
(NOACs) are more convenient than is warfarin
because they can be given in ﬁxed doses without
routine coagulation monitoring. In Canada, 3 NOACs
are currently available: the oral thrombin inhibitor
dabigatran etexilate, and the oral factor Xa inhibitors
rivaroxaban and apixaban.
Although the NOACs were ﬁrst approved in 2008
for the prevention of venous thromboembolism (VTE)
after elective hip- or knee-replacement surgery, the
most common use of the NOACs now is for stroke
risk reduction in patients with atrial ﬁbrillation (AF).3
More recently, the NOACs were also approved for the
treatment of deep vein thrombosis and pulmonary
embolism.4–6
Little is known about the trends of prescribing
OACs in Canada. This article provides the ﬁrst look at
OAC-prescribing trends in Canada, according to
province and physician specialty, since the availability
of the NOACs in 2008. Guidelines have embraced the
use of NOACs, and in 2012, the Canadian Cardio-
vascular Society gave preference to NOACs over
warfarin for stroke prevention in AF.7 However, a
major challenge for clinicians in following this
recommendation is the lack of alignment with
reimbursement systems in Canada.8,9 An understand-
ing of the uptake of NOACs may help to change
policy/reimbursement strategies to reﬂect current
guidelines and prescribing patterns.
MATERIALS AND METHODS
Data Sources
A detailed listing and description of the data
sources are provided in the Supplemental Material in
the online version at http://dx.doi.org/10.1016/j.
clinthera.2015.09.008. Brieﬂy, data on the numbers
of prescriptions ﬁlled by retail pharmacies in Canada
from January 2008 to June 2014, available from the
Canadian CompuScript database, were obtained from
IMS Health Canada Inc. These data provide the
number of new, reﬁll, and total prescription volumes
for OACs, including formulation and strength, within
each therapeutic class, at the national and provincial
levels. The Physician Specialty Report, which can
complement the Canadian Compuscript, shows new
and total prescriptions dispensed according to
physician specialty, specialty share by product and
therapeutic class, and product market share byNovember 2015physician specialty. Data are available from Alberta,
Saskatchewan, Ontario, Quebec, Nova Scotia, and
New Brunswick; the other provinces and territories do
not supply data to IMS Health Canada Inc. IMS
Health Canada Inc captures all new and reﬁll
prescriptions (80% national prescription coverage)
from a panel of over 5000 pharmacies, which are
stratiﬁed by province, pharmacy type (retail chain,
independent), and size. Prescription records are
collected electronically and updated on a monthly
basis. Sample data from the panel are extrapolated to
estimate the prescriptions by all physicians in each
province. The accuracy of these data is greater in
provinces with greater pharmacy coverage.
Extrapolated provincial totals were summed to
provide a national estimate. Total prescriptions
refers to all new and reﬁll prescriptions dispensed
from pharmacies. Data on each of the NOACs in all
of the commonly used doses were obtained:
dabigatran (75, 110, and 150 mg), rivaroxaban
(10, 15, and 20 mg), and apixaban (2.5 and 5 mg).
The total prescription share for each OAC was used
for accounting for differences in NOAC dosing. For
analysis of the per capita OAC-prescribing trends by
province, the total number of pills was used for
accounting for differences in prescription duration,
thereby ensuring that provinces with shorter prescrip-
tion durations (eg, Quebec) would not be over-
represented.
Data for determining the total prescriptions by
indication were obtained from the Canadian Disease
and Therapeutic Index (CDTI). The CDTI uses
statistical information on the patterns and treatment
of diseases encountered in ofﬁce-based practices in
Canada to help to understand disease trends and
drug-prescribing patterns. Data on estimated drug
use and estimated diagnostic visits are obtained at
national and regional levels (5 regions: Maritimes,
Quebec, Ontario, Prairies, and British Columbia)
from physicians who ﬁll out case records about their
patients. The CDTI panel consists of 652 physicians
in ofﬁce-based medical practices covering 15 special-
ties. Each quarter, these physicians report on
patients’ visits during a 2-day period. Data from
the CDTI do not include visits to non–primary care
specialists or reﬂect patient self-medication. Although
individual quarterly estimates of the national CDTI
data have a high sampling error because of large
sampling weights, quarterly and year-over-year2507
Clinical Therapeuticsestimates are accurate compared with those of other
drug expenditures and health care services uti-
lization statistics.10
To assess factors that inﬂuence prescription changes,
the numbers of NOAC prescriptions were also ana-
lyzed in relation to the timing of provincial reimburse-
ment. In Canada (with the exception of Quebec), the
decision to add a newly licensed nononcologic drug to
provincial formulary listings is based on recommenda-
tions by the Canadian Agency for Drugs and Tech-
nologies in Health Common Drug Review (CDR).11
The CDR not only evaluates the evidence supporting
the efﬁcacy and tolerability of a drug but also performs
a pharmacoeconomic assessment. Based on the CDR
ﬁndings, the Canadian Expert Drug Advisory
Committee makes a ﬁnal recommendation, which is
used by the provinces to decide whether a new drug
should be added to the provincial formulary. In
Quebec, the Institut National d’Excellence en Santé et
en Services Sociaux provides recommendations on
whether to add new drugs to the formulary.12
Methodology for Estimating OAC Total
Prescriptions by Indication
Factors by indication have been derived from the
CDTI, based on the number of drug mentions by
indication. The CDTI physician panel is instructed to
record the diagnosis identiﬁed or treated during each
patient visit. Information on diagnoses is coded by the
IMS Health coders using the World Health Organ-
ization’s International Classiﬁcation of Diseases,
Ninth Revision. Factors by indication are then applied
to total prescriptions available from CompuScript to
generate total prescriptions by indication.
RESULTS
Trends of OAC Prescribing by Orthopedic
Surgeons in Canada
Health Canada ﬁrst approved the use of dabigatran
and rivaroxaban in 2008 and apixaban in 2011 for
the prevention of VTE after elective hip- or knee-
replacement surgery. Whereas rivaroxaban and apix-
aban received positive CDR recommendations in 2008
and 2012, respectively, dabigatran received a negative
CDR recommendation in 2009.10,13,14
To determine the impact of the NOACs on VTE
prevention after hip or knee arthroplasty, we reviewed
trends of prescribing by orthopedic surgeons because
they rarely prescribe OACs for other indications.2508Based on prescribing data in this specialty group,
there has been a shift from warfarin and injectable
anticoagulants to rivaroxaban (Figure 1). The largest
increase in rivaroxaban prescribing occurred between
2009 and 2010, which corresponds to the timeframe
when rivaroxaban was ﬁrst listed on most provincial
formularies (see Supplemental Table in the online
version at http://dx.doi.org/10.1016/j.clinthera.2015.
09.008). By 2013, rivaroxaban held a 55% share of
the anticoagulant market in orthopedics, whereas
dabigatran and apixaban together accounted for
approximately 3%.
Overall OAC-Prescribing Trends in Canada
Apart from prescriptions generated by orthope-
dic surgeons, identifying the particular conditions
for which OACs were prescribed is challenging
because of their multiple approved indications and
somewhat overlapping doses. Given the prevalences
of AF and VTE and the number of arthroplasties
per year, as well as current standards of care, we
estimated that AF, VTE treatment, and thrombo-
prophylaxis in orthopedic surgery account for
59%, 10%, and 1%, respectively, of all OAC
prescriptions.15 Although warfarin is used in the
treatment of more conditions than are the NOACs,
for this article we did not downward-adjust the
warfarin-prescribing data to account for this when
comparing prescription data between warfarin and
the NOACs.
The total number of OAC prescriptions steadily
increased, from 4.8 to 7 million from 2008 to
2013 (Figure 2A). Warfarin prescriptions increased
until 2011, after which the number of warfarin
prescriptions decreased and an increase in
prescriptions for the NOACs was observed. The
proportion of OAC prescriptions for warfarin fell
from 99% in 2010 to 67% by June 2014
(Figure 2B). The decline in warfarin prescribing
occurred during the same timeframe as the positive
CDR recommendations for the use of dabigatran
(2011), rivaroxaban (2012), and apixaban (2013)
for stroke prevention in AF.16–18 There was a signiﬁ-
cant increase in the prescribing of dabigatran before
its positive recommendation from the CDR; dabiga-
tran prescribing accelerated with its addition to
provincial formularies (see Supplemental Table in
the online version at http://dx.doi.org/10.1016/
j.clinthera.2015.09.008). By contrast, the marketVolume 37 Number 11
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Figure 1. Share of orthopedic surgeons’ prescriptions of anticoagulant agents. Dates of Common Drug
Review (CDR) recommendations for venous thromboembolism prevention after major orthopedic
surgery are shown for each non–vitamin K oral anticoagulants. *Dabigatran received a negative
CDR recommendation. Source: IMS Brogan Canadian Compuscript Physician Specialty Report.
J.I. Weitz et al.shares of rivaroxaban and apixaban increased only
after they were added to provincial formularies.
OAC-Prescribing Trends, by Physician Subgroup
Since 2010, the proportionate prescribing of
NOACs was highest among cardiologists and neurol-
ogists (see Supplemental Figure 1A and 1D in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.09.008). By 2013, warfarin accounted for 45%
and 51% of the total OAC prescriptions by cardio-
logists and neurologists, respectively (Figure 3). The
proportionate share of dabigatran among the NOACs
was surpassed in late 2013 by rivaroxaban, which
gained 28% and 18% of the OAC market among
cardiologists and neurologists, respectively, by June
2014 (see Supplemental Figure 1A and 1D in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.09.008). Apixaban prescribing within these 2
specialties has steadily increased, gaining 18% of the
market by cardiologists and neurologists, by the second
quarter (Q2) of 2014 (see Supplemental Figure 1ANovember 2015and 1D in the online version at http://dx.doi.org/10.
1016/j.clinthera.2015.09.008). By comparison, the
increase in prescribing of the NOACs has been more
gradual among internists, general practitioners,
emergency department physicians, and hematologists,
among whom warfarin retained 68% to 89% of the
total OAC prescription share in 2013 (Figure 3). By
Q2 2014, 57% of OAC prescriptions by internists
were for warfarin (see Supplemental Figure 1B in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.09.008), and warfarin represented 71% and
83% of OAC prescriptions from general practitioners
and hematologists, respectively (see Supplemental
Figure 1C and 1E in the online version at http://
dx.doi.org/10.1016/j.clinthera.2015.09.008).
OAC-Prescribing Trends by Province
Across Canada, the greatest per capita usage of
OACs was in New Brunswick, Nova Scotia, and
Saskatchewan (Figure 4). Alberta and Manitoba had
the lowest per capita OAC prescribing, whereas per2509
2008 2009 2010 2011 2012
apixaban 0 0 0 0 296
rivaroxaban 263 8,213 25,855 41,518 130,454
dabigatran etexilate 141 1,324 9,586 390,503 851,855
warfarin 4,804,647 5,396,701 5,634,072 5,776,816 5,626,882
2013
38,699
640,536
973,290
5,368,792
0
1
2
3
4
5
6
7
8
To
ta
l P
re
sc
ri
pt
io
ns
 (
M
ill
io
ns
)
6.2M
6.6M
7.0M
4.8M
5.4M
5.7M
Total OAC 4,805,051 5,406,238 5,669,513 6,208,837 6,609,487 7,021,317
A
0.0%
20.0%
40.0%
60.0%
dab
igat
ran 
(CD
R)
riva
roxa
ban
 (CD
R)
apix
aba
n (C
DR)
80.0%
100.0%
120.0%
Ja
n-
08
A
pr
-0
8
Ju
l-0
8
O
ct
-0
8
Ja
n-
09
A
pr
-0
9
Ju
l-0
9
O
ct
-0
9
Ja
n-
10
A
pr
-1
0
Ju
l-1
0
O
ct
-1
0
Ja
n-
11
A
pr
-1
1
Ju
l-1
1
O
ct
-1
1
Ja
n-
12
A
pr
-1
2
Ju
l-1
2
O
ct
-1
2
Ja
n-
13
A
pr
-1
3
Ju
l-1
3
O
ct
-1
3
Ja
n-
14
A
pr
-1
4
Sh
ar
e 
of
 O
ra
l A
nt
ic
oa
gu
la
nt
s 
To
ta
l P
re
sc
ri
pt
io
n
apixaban
rivaroxaban
dabigatran etexilate
warfarin
B
Figure 2. Total annual prescription volumes (A) and total monthly prescription shares (B) of oral
anticoagulant (OAC) agents. Dates of Common Drug Review recommendations of each of the
non–vitamin K antagonist OACs (NOACs) for stroke prevention in patients with atrial fibrillation
are shown. Data on warfarin have not been adjusted to account for the fact that the approved
indications for the NOACs represent only 70% of all OAC prescriptions. Source: IMS Brogan
Canadian Compuscript.
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Figure 3. Total number of prescriptions for oral anticoagulants (OACs) prescribed by each physician
specialty in 2013. Data on warfarin have not been adjusted to account for the fact that
the approved indications for the non–vitamin K antagonist OACs (NOACs) represent only
70% of all OAC prescriptions. Source: IMS Brogan Canadian Compuscript Physician
Specialty Report.
J.I. Weitz et al.capita usage in British Columbia, Ontario, Quebec,
Newfoundland, and Prince Edward Island was similar
to the national average. For the provinces that were
analyzed further (Ontario, Quebec, British Columbia,
Alberta, Saskatchewan, Manitoba, New Brunswick,
and Nova Scotia), dabigatran prescribing increased
before provinces reimbursed the costs of stroke
prevention in AF. The only exception to this ﬁnding
was Quebec, where dabigatran prescriptions increased
around the same time that reimbursement was
approved (see Supplemental Figure 2 in the online
version at http://dx.doi.org/10.1016/j.clinthera.2015.
09.008). This ﬁnding differs from the trends of
increased prescribing of rivaroxaban and apixaban,
the market growth of which increased only after
reimbursement approval. The most rapid decline in
warfarin use was in Ontario, where 57% of OAC
prescriptions were for warfarin by the end of Q2November 20152014, compared with 98% in Q4 2010 (see
Supplemental Figure 2A in the online version at
http://dx.doi.org/10.1016/j.clinthera.2015.09.008).
By comparison, warfarin accounted for 68% to 76%
of OAC prescriptions in British Columbia, Alberta,
Saskatchewan, Manitoba, Quebec, New Brunswick,
and Nova Scotia.
DISCUSSION
Our analysis of OAC-prescribing trends in Canada
reveals an increase in overall OAC prescriptions since
2008, with an increase in the absolute number of
warfarin prescriptions to 2011 followed by decreasing
numbers since then. An analogous trend in OAC
prescriptions has been reported among European
countries, where, as in Canada, vitamin K antagonists
still represent the majority of OAC prescriptions,
despite the fact that several practice guidelines give2511
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Figure 4. The number of oral anticoagulant (OAC) pills dispensed per capita for each Canadian province in
2013. Per capita OAC pills dispensed in each province were calculated by dividing the total OAC
pills dispensed by the size of the population. Data do not include acenocoumarol, which has
o0.5% market share; data on Canada do not include the Yukon and Northwest Territories. Source:
IMS Brogan Canadian Compuscript and CANSIM, table 051-0001 (population as of July 1, 2013).
Clinical Therapeuticspreference to the NOACs over warfarin for stroke
prevention in the majority of patients with AF.8,19–22
There is considerable variation in the proportionate
prescribing of warfarin and NOACs among physician
subgroups. Based on the ﬁndings, the NOACs have
been predominantly embraced by specialists, in partic-
ular, orthopedic surgeons, cardiologists, and neurolo-
gists. This ﬁnding is not surprising given that the most
of the established indications for the NOACs are for
thromboprophylaxis after hip or knee arthroplasty and
stroke prevention in AF. Orthopedic surgeons rarely
prescribe OACs for indications other than thrombopro-
phylaxis, and cardiologists and stroke neurologists are
the specialists most frequently involved in the treatment
of patients with AF and patients with AF-related stroke,
respectively. The increasing prescribing of NOACs is
likely inﬂuenced by the Canadian Cardiovascular Soci-
ety guidelines, which give preference to NOACs over
warfarin in most patients with nonvalvular AF.7,8,23
The growing prescribing of NOACs among physicians
can also be attributed to the expanding number of
indications for which the NOACs have been approved,
in particular, the treatment of deep vein thrombosis and
pulmonary embolism.
Of the NOACs, rivaroxaban acquired a substantial
portion of the market share for anticoagulants for2512VTE prevention after major orthopedic surgery, be-
cause it was the ﬁrst of the NOACs to be given a
positive CDR recommendation.13 Although apixaban
was given a positive CDR recommendation for VTE
prevention in orthopedics in 2012, it did not gain an
appreciable market share, likely because most
institutions already had incorporated rivaroxaban
into their orthopedic care pathways and saw no
advantage in introducing a second agent.
Multiple factors are likely involved in the differ-
ences in OAC-prescribing trends across the provin-
ces. The choice between warfarin and a NOAC may
be inﬂuenced by the availability of anticoagulation
clinics and laboratories for international normalized
ratio monitoring; in areas with limited access,
NOACs may be preferred over warfarin because
the use of NOACs does not require routine coagu-
lation monitoring. The choice of therapy may also be
affected by a patient’s level of public or private
insurance due to the higher cost of NOACs relative
to warfarin.24
Although this analysis provides a robust assessment
of OAC-prescribing trends in Canada, it had some
limitations. First, OAC-prescribing data by physician
specialty are available only from Alberta, Saskatch-
ewan, Ontario, Quebec, Nova Scotia, and NewVolume 37 Number 11
J.I. Weitz et al.Brunswick; therefore, the results of the analysis of
physician-speciﬁc trends cannot be accurately extrapo-
lated across all provinces. Second, OAC prescriptions
by physician subgroup were not stratiﬁed by indica-
tion; thus, changes in OAC-prescribing trends by each
specialty could not be tracked according to their
speciﬁc therapeutic use by each subgroup. Finally,
this article does not provide information on prescrip-
tions at the patient level, but rather looks at total
prescriptions, preventing extrapolation to speciﬁc
patient subgroups or disease trends.
Overall, the data show that NOACs represent a
growing segment of the OAC market, with an overall
decline in warfarin use and increased prescribing of
the NOACs. An understanding of the increase in
prescribing of the NOACs can aid in knowledge
translation and promote the appropriate prescribing
of these agents for current and new indications.
Ongoing trials of the NOACs are exploring their
tolerability and efﬁcacy in novel clinical settings,
including stroke prevention in patients with embolic
stroke of undetermined source (dabigatran:
RESPECT-ESUS [Dabigatran Etexilate for Secondary
Stroke Prevention in Patients With Embolic Stroke of
Undetermined Source], NCT02239120; rivaroxaban:
NAVIGATE ESUS [Rivaroxaban Versus Aspirin in
Secondary Prevention of Stroke and Prevention of
Systemic Embolism in Patients With Recent Embolic
Stroke of Undetermined Source], NCT02313909),
stroke prevention in patients with AF undergoing
cardioversion (edoxaban: ENSURE-AF [Edoxaban
vs. Warfarin in Subjects Undergoing Cardioversion
of Atrial Fibrillation], NCT02072434), and preven-
tion of major adverse cardiovascular events in patients
with coronary or peripheral artery disease (rivarox-
aban: COMPASS [Rivaroxaban for the Prevention of
Major Cardiovascular Events in Coronary or Periph-
eral Artery Disease], NCT01776424). With potential
new indications, increasing awareness of the impor-
tance of stroke prevention in AF patients, and growing
experience with NOACs, the trend for increased
NOAC prescribing is expected to continue.
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Supplementary Methods
There were three main data sources used for the
publication:i.NIMS Brogan Canadian CompuScript Audit (of
which the Physician Specialty Report is an exten-
sion of this audit)ii. IMS Brogan Canadian Disease and Therapeutic
Index (CDTI)iii. CANSIM - Statistics Canada’s key socioeconomic
databaseA) IMS Brogan Canadian CompuScript Audit is the
main data source of all the prescription data.
The Canadian CompuScipt Audit provides data
on prescriptions dispensed by retail pharmacies.
The prescription data is reported at National and
Provincial level. An extension of the CompuScript
Audit is the Physician Specialty Report which
provides the same data by physician specialties.
Data is collected through a panel of over 5,600
retail pharmacies. The data is then projected to
estimate prescriptions activity for retail pharmacies
not on IMS Brogan panel. See below for type of
pharmacies included/excluded and information
collected:
Included:i. Retail pharmacies (chain & independent)
ii. Mass-merchandisers with pharmacies
iii. Groceries with pharmacies
iv. Stores of all sizes
v. Pharmacies with Internet-free business (not in-
cluded in sample, but are in the universe)ovember 2015Excluded:i. Hospital dispensariesThe following information is collected:i. Product name
ii. Manufacturer name
iii. Product form/strength
iv. Prescription type: new or reﬁll
v. Prescription size
vi. Prescription price (including the dispensing fee
and mark up)
vii. Pharmacy ID
viii. MD license number (excluding British Columbia
and Manitoba)B) IMS Brogan Canadian Disease and Therapeutic
Index (CDTI)
The Canadian Disease and Therapeutic Index (CDTI)
is an IMS Brogan report that provides information on
disease trends and treatments, including the therapeutic
use of prescription medications by ofﬁce-based physicians
(approximately 650) stratiﬁed by region, and representing
all major specialties. Each physician reports quarterly,
over two consecutive days in which he/she has patient
contact. Data from the CDTI does not include visits to
non-primary specialties, such as anesthesiologists and
pathologists, or reﬂect patient self-medication.
C) CANSIM is Statistics Canada’s key socioeconomic
database and includes data on Canadian population.
Data is collected through census and various surveys
conducted by Statistics Canada over the years.2514.e1
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Supplementary Figure S1. Rate of OAC uptake by physician specialty: cardiologists (A), internists (B),
hematologists (C), neurologists (d) and general practitioners (E). Warfarin data
have not been adjusted to account for the fact that the approved indications for
the NOACs only represent 70% of all OAC prescriptions. Source: IMS Health
Canada Inc. (Brogan) Canadian Compuscript Physician Specialty Report.
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Supplementary Table SI. Dates of provincial formulary listing for each of the NOACs for stroke prevention in
AF and VTE prevention after major orthopaedic surgery.
AF Stroke Prevention VTE – Orthopaedics*
Dabigatran Rivaroxaban Apixaban Rivaroxaban Apixaban
Month Year Month Year Month Year Month Year Month Year
Alberta 05 2012 10 2012 03 2014 04 2009 09 2012
British Columbia 05 2012 08 2012 09 2013 07 2010 12 2013
Manitoba 09 2012 09 2012 10 2013 08 2009 04 2014
New Brunswick 06 2012 09 2012 11 2014 06 2009 11 2014
Nova Scotia 06 2012 09 2012 12 2013 06 2009 05 2014
Ontario 04 2012 07 2012 08 2013 06 2009 08 2013
Que´bec 04 2011 10 2012 10 2013 06 2009 Not Listed
Saskatchewan 05 2012 08 2012 11 2013 04 2009 04 2014
*Dabigatran is not reimbursed for VTE prevention after major orthopaedic surgery.
J.I. Weitz et al.
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